Compare · ARGX vs TWST
ARGX vs TWST
Side-by-side comparison of argenx SE (ARGX) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $54.47B, about 10.0x TWST ($5.45B).
- Over the past year, ARGX is up 62.0% and TWST is up 148.0% - TWST leads by 86.0 points.
- TWST has been more active in the news (11 items in the past 4 weeks vs 2 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 14 for TWST).
- Company
- argenx SE
- Twist Bioscience Corporation
- Price
- $877.93-1.58%
- $87.53+5.58%
- Market cap
- $54.47B
- $5.45B
- 1M return
- +10.09%
- +76.72%
- 1Y return
- +61.95%
- +148.00%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 2
- 11
- Recent ratings
- 25
- 14
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest TWST
- SEC Form S-3ASR filed by Twist Bioscience Corporation
- SVP of Human Resources Green Paula exercised 26,137 shares at a strike of $23.33 and sold $2,134,488 worth of shares (26,137 units at $81.67) (SEC Form 4)
- Canaccord Genuity initiated coverage on Twist Bioscience with a new price target
- Officer Cho Dennis sold $28,077 worth of shares (402 units at $69.84), decreasing direct ownership by 0.33% to 119,692 units (SEC Form 4) (tax liability)
- SVP of Human Resources Green Paula sold $61,742 worth of shares (884 units at $69.84), decreasing direct ownership by 0.73% to 120,705 units (SEC Form 4) to cover taxes
- Chief Executive Officer Leproust Emily M. sold $158,197 worth of shares (2,265 units at $69.84), decreasing direct ownership by 0.27% to 844,607 units (SEC Form 4) (for withholding tax)
- Chief Accounting Officer Werner Robert F. sold $94,046 worth of shares (1,359 units at $69.20) and gifted 500 shares, decreasing direct ownership by 4% to 46,327 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Laponis Adam sold $280,000 worth of shares (4,000 units at $70.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 112,675 units (SEC Form 4)
- Officer Cho Dennis sold $990,799 worth of shares (14,205 units at $69.75) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 120,094 units (SEC Form 4)
- Director Starovasnik Melissa A. sold $170,000 worth of shares (2,500 units at $68.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 22,222 units (SEC Form 4)